P4–410: Steady–state pharmacokinetics of rivastigmine in patients with mild to moderate Alzheimer's disease are not affected by co–administration of memantine

Background and objective: It has been shown that combining memantine and a cholinesterase inhibitor, which each affect different neurotransmitter systems, may offer further improvements in efficacy over either treatment alone in patients with Alzheimer’s disease. The present study was conducted to determine if memantine has any effects on the steady-state pharmacokinetics of rivastigmine in patients with mild to moderate Alzheimer’s disease.